These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 15458450)

  • 1. Effect of fluvastatin on renal end points in the Assessment of Lescol in Renal Transplant (ALERT) trial.
    Fellström B; Holdaas H; Jardine AG; Holme I; Nyberg G; Fauchald P; Grönhagen-Riska C; Madsen S; Neumayer HH; Cole E; Maes B; Ambühl P; Olsson AG; Hartmann A; Logan JO; Pedersen TR;
    Kidney Int; 2004 Oct; 66(4):1549-55. PubMed ID: 15458450
    [TBL] [Abstract][Full Text] [Related]  

  • 2. No detrimental effect on renal function during long-term use of fluvastatin in renal transplant recipients in the Assessment of Lescol in Renal Transplantation (ALERT) study.
    Fellström B; Abedini S; Holdaas H; Jardine AG; Staffler B; Gimpelewicz C;
    Clin Transplant; 2006; 20(6):732-9. PubMed ID: 17100723
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of fluvastatin on cardiac outcomes in kidney transplant patients with systemic lupus erythematosus: a randomized placebo-controlled study.
    Norby GE; Holme I; Fellström B; Jardine A; Cole E; Abedini S; Holdaas H;
    Arthritis Rheum; 2009 Apr; 60(4):1060-4. PubMed ID: 19333947
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Risk factors for reaching renal endpoints in the assessment of Lescol in renal transplantation (ALERT) trial.
    Fellström B; Holdaas H; Jardine AG; Nyberg G; Grönhagen-Riska C; Madsen S; Neumayer HH; Cole E; Maes B; Ambühl P; Olsson AG; Staffler B; Pedersen TR;
    Transplantation; 2005 Jan; 79(2):205-12. PubMed ID: 15665769
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Osteoprotegerin as a predictor of renal and cardiovascular outcomes in renal transplant recipients: follow-up data from the ALERT study.
    Svensson M; Dahle DO; Mjøen G; Weihrauch G; Scharnagl H; Dobnig H; März W; Jardine A; Fellström B; Holdaas H
    Nephrol Dial Transplant; 2012 Jun; 27(6):2571-5. PubMed ID: 22172725
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of fluvastatin on cardiac outcomes in renal transplant recipients: a multicentre, randomised, placebo-controlled trial.
    Holdaas H; Fellström B; Jardine AG; Holme I; Nyberg G; Fauchald P; Grönhagen-Riska C; Madsen S; Neumayer HH; Cole E; Maes B; Ambühl P; Olsson AG; Hartmann A; Solbu DO; Pedersen TR;
    Lancet; 2003 Jun; 361(9374):2024-31. PubMed ID: 12814712
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of fluvastatin on acute renal allograft rejection: a randomized multicenter trial.
    Holdaas H; Jardine AG; Wheeler DC; Brekke IB; Conlon PJ; Fellstrøm B; Hammad A; Holme I; Isoniemi H; Moore R; Rowe PA; Sweny P; Talbot DA; Wadstrøm J; Østraat Ø
    Kidney Int; 2001 Nov; 60(5):1990-7. PubMed ID: 11703619
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inflammation-associated graft loss in renal transplant recipients.
    Dahle DO; Mjøen G; Oqvist B; Scharnagl H; Weihrauch G; Grammer T; März W; Abedini S; Norby GE; Holme I; Fellström B; Jardine A; Holdaas H
    Nephrol Dial Transplant; 2011 Nov; 26(11):3756-61. PubMed ID: 21511816
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of fluvastatin on cardiac events in renal transplant patients: ALERT (Assessment of Lescol in Renal Transplantation) study design and baseline data.
    Holdaas H; Fellström B; Holme I; Nyberg G; Fauchald P; Jardine A; Grönhagen-Riska C; Madsen S; Neumayer HH; Cole E; Maes B; Weinreich T; Olsson AG; Pedersen TR; Benghozi R; Hartmann A;
    J Cardiovasc Risk; 2001 Apr; 8(2):63-71. PubMed ID: 11324372
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of fluvastatin on hyperlipidemia after renal transplantation.
    Tokumoto T; Tanabe K; Ishida H; Shimmura H; Ishikawa N; Goya N; Akiba T; Toma H
    Transplant Proc; 2004 Sep; 36(7):2141-4. PubMed ID: 15518777
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Homoarginine and Clinical Outcomes in Renal Transplant Recipients: Results From the Assessment of Lescol in Renal Transplantation Study.
    Drechsler C; Pihlstrøm H; Meinitzer A; Pilz S; Tomaschitz A; Abedini S; Fellstrom B; Jardine AG; Wanner C; März W; Holdaas H
    Transplantation; 2015 Jul; 99(7):1470-6. PubMed ID: 25675199
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ramipril versus placebo in kidney transplant patients with proteinuria: a multicentre, double-blind, randomised controlled trial.
    Knoll GA; Fergusson D; Chassé M; Hebert P; Wells G; Tibbles LA; Treleaven D; Holland D; White C; Muirhead N; Cantarovich M; Paquet M; Kiberd B; Gourishankar S; Shapiro J; Prasad R; Cole E; Pilmore H; Cronin V; Hogan D; Ramsay T; Gill J
    Lancet Diabetes Endocrinol; 2016 Apr; 4(4):318-26. PubMed ID: 26608067
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effect of fluvastatin of hyperlipidemia in renal transplant recipients: a prospective, placebo-controlled study.
    Türk S; Yildiz A; Tükek T; Akkaya V; Aras U; Türkmen A; Uras AR; Sever MS
    Int Urol Nephrol; 2001; 32(4):713-6. PubMed ID: 11989571
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of fluvastatin extended-release (80 mg) alone and in combination with ezetimibe (10 mg) on low-density lipoprotein cholesterol and inflammatory parameters in patients with primary hypercholesterolemia: a 12-week, multicenter, randomized, open-label, parallel-group study.
    Alvarez-Sala LA; Cachofeiro V; Masana L; Suarez C; Pinilla B; Plana N; Trias F; Moreno MA; Gambus G; Lahera V; Pintó X
    Clin Ther; 2008 Jan; 30(1):84-97. PubMed ID: 18343245
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of fluvastatin on homocysteine and serum lipids in kidney allograft recipients.
    Małyszko J; Małyszko JS; Brzósko S; Pawlak K; Myśliwiec M
    Ann Transplant; 2002; 7(1):52-4. PubMed ID: 12221904
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Graft loss risk in renal transplant recipients with metabolic syndrome: subgroup analyses of the ALERT trial.
    Soveri I; Abedini S; Holdaas H; Jardine A; Eriksson N; Fellström B
    J Nephrol; 2012; 25(2):245-54. PubMed ID: 21725919
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fluvastatin slow-release lowers platelet-activating factor acetyl hydrolase activity: a placebo-controlled trial in patients with type 2 diabetes.
    Winkler K; Abletshauser C; Friedrich I; Hoffmann MM; Wieland H; März W
    J Clin Endocrinol Metab; 2004 Mar; 89(3):1153-9. PubMed ID: 15001601
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fluvastatin decreases soluble thrombomodulin in cardiac transplant recipients.
    Ambrosi P; Aillaud MF; Habib G; Kreitmann B; Métras D; Luccioni R; Bouvenot G; Juhan-Vague I
    Thromb Haemost; 2000 Jan; 83(1):46-8. PubMed ID: 10669153
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cerebrovascular events in renal transplant recipients.
    Abedini S; Holme I; Fellström B; Jardine A; Cole E; Maes B; Holdaas H;
    Transplantation; 2009 Jan; 87(1):112-7. PubMed ID: 19136900
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effect of fluvastatin on cardiac outcomes in patients with moderate to severe renal insufficiency: a pooled analysis of double-blind, randomized trials.
    Holdaas H; Wanner C; Abletshauser C; Gimpelewicz C; Isaacsohn J
    Int J Cardiol; 2007 Apr; 117(1):64-74. PubMed ID: 16889855
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.